The effects of microsomal enzym e inducers on thyroid hormone hom eostasis and the thyroid gland are of concern. We have investigated the effects of microsom al enzym e inducers on thyroid follicular cell proliferation and thyroid hormone metabolism in rats. We have shown that small increases in serum TSH can result in large increases in thyroid follicular cell proliferation. Furtherm ore, only those microsom al enzym e inducers that increase serum TSH-that is, phenobarbi tal (PB) and pregnenolo ne-16 -carbonitrile (PCN)increase thyroid follicular cell proliferation, whereas those m icrosoma l enzym e inducers that do not increase serum TSHthat is, 3-methylcholanthrene (3M C) and Aroclor 1254 (PCB)do not increase thyroid follicular cell proliferation. Deiodination does not appear to be the reason why serum T 3 concentrations are maintained in microsomal enzym e inducer-treated rats. We have also shown that those m icrosoma l enzym e inducers that increase serum TSH increase T 3 UDP-glucurono syltransferase (UGT) activity, whereas those microsomal enzym e inducers that do not increase serum TSH do not increase T 3 UGT activity. This nding suggests that induction of T 3 glucuronidation, rather than T 4 glucuronidation, mediates increases in serum TSH of microsomal enzym e inducer treated rats.
INTRODUCTION Thyroid Cancer in Humans
The incidence of thyroid cancer in humans has been estimated to be between 1 and 10 per 100,000 people. Gender, age, iodine de ciency, and exposure to radiation are known risk factors that increase the developm ent of thyroid cancer (11) . The link between radiation and thyroid cancer was rst documented in the 1950s, when it was reported that nearly 50% of children treated for thyroid cancer had previously been exposed to head and neck x-ray irradiation. Also, there was an increased incidence of thyroid cancers in people of Hiroshima and Nagasaki that were exposed to radiation from the atom ic bomb in 1945, which was inversely related to age and the distance from the epicenter (3) .
The link between radioactive iodide (eg, 131 I) and thyroid cancer has been extensively investigated in people exposed to radioactive fallout from the nuclear accident at Chernobyl in 1986. Epidem iological studies from the Chernobyl accident indicate that children, less than 15 years of age, are much m ore sensitive to 131 I because the incidence of thyroid cancer in these children increased as early as 3 years after the accident and not in adults (27) . The incidence of thyroid cancer in children exposed to radioactive fallout from the Chernobyl accident has been shown to be inversely proportional to age as well as to the distance from the nuclear reactor site (3, 27) . The increased sensitivity of children, compared to adults, to the thyroid tumor-producing effects of radiation is thought to be due to elevated serum concentrations of thyroid-stimulating hormone (TSH) that children typically have during the rst decade of life (10) .
TSH is thought to be important in the development of thyroid tum ors in children. TSH has also been implicated in playing a role in thyroid tumorigenesis in adults. Studies have shown that in geographic areas of iodine deciency, a condition marked by elevated serum TSH concentrations, iodine supplementation reduces the incidence of thyroid follicular cell tumors in adults (37) . Also, people af icted with dyshormonogenesis, caused by a defect in the synthesis of thyroid horm ones by the thyroid gland, have high serum TSH concentrations and a high incidence of thyroid follicular cell tumors (37) .
Thyroid Cancer in Rats
As in humans, iodine de ciency in rats is associated with the development of thyroid follicular cell tum ors (37) . Also, long-term treatm ent of rats with antithyroid drugs, which inhibit thyroid hormone synthesis by the thyroid gland, results in an increased incidence of thyroid tumors (19) . Antithyroid drugs are thought to be nongenotoxic because they do not m utate genes important in cellular division. Thyroid tum ors produced by antithyroid drugs can be reduced if rats are also treated with triiodothyronine (T 3 ) or are hypophy sectomized [ie, removal of the pituitary (20) ]. Exposure of rats to radiation also results in the development of thyroid tumors, which can be enhanced by increasing serum TSH concentration [eg, adm inistration of an antithyroid drug (6, 22) ]. Again, thyroid horm one replacement therapy-that is, treatment with thyroxine (T 4 ) and/or T 3 -reduces the incidence of thyroid tumors in rats treated with a genotoxin (eg, radiation), followed by a nongenotoxin [eg, an antithyroid drug (37) ]. The role of TSH in thyroid tum origenesis is considered to be through a nongenotoxic m echanism(s) (ie, growth prom otion). TSH is known to stim ulate thyroid gland growth (28, 38) .
Several studies have investigated thyroid hyperplasia EFFECTS ON T 4 , T 3 , AND THE THYROID These data have been reported in a previous publication (14) . and tumor development subsequent to phenobarbital (PB) treatment. The incidence of thyroid tumors, after initiation by nitrosamine treatment, increased dram atically in rats treated with PB (12, 13) . The ability of PB to promote thyroid tum ors has been shown to be attenuated by readm inistration of thyroid hormones (T 4 and T 3 ) in rats initiated with a nitrosamine and subsequently with PB (26) . From this observation, it was suggested that thyroid hyperplasia and tumor developm ent were secondary to PB -induced thyroid hormone biotransformation and excretion, resulting in stimulation of the thyroid gland by TSH (26) . It was suggested that increased TSH concentration, but not PB itself, produced thyroid hyperplasia and tumor development.
Proposed Mechanism of Thyroid Tumor Promotion in Rats
The mechanism by which microsomal enzyme inducers affect the thyroid gland is a m ultistep process. The originally proposed mechanism of thyroid tum or promotion is shown in Figure 1 and is based on studies in which rats were treated with PB (24, 25) . The steps include (a) increased hepatic disposition of T 4 , which (b) reduces serum T 4 concentration. To compensate for the reduced serum T 4 concentration, (c) serum TSH concentration increases, which stimulates (d) thyroid follicular cell proliferation and (e) ultim ately neoplasia.
The effects of microsom al enzyme inducers that increase T 4 glucuronidation, as well as reduce serum T 4 , on serum TSH and the thyroid gland are unclear because we have shown ( Figure 2 ) that only some m icrosomal enzyme inducers-that is, PB and pregnenolone-16 -carbonitrile (PCN)-increase serum TSH, whereas other m icrosom al enzym e inducers-that is, 3 -m ethylcholanthrene (3MC) and Aroclor 1254 (PCB)-do not increase serum TSH (14, 23) . It is generally thought that reduc-tions in serum T 4 mediate the increase in serum TSH concentration observed in rats treated with PB (24) .
Effects of Microsomal Enzyme Inducers on Thyroid Gland Growth
Until recently, studies investigating the effects of m icrosom al enzyme inducers on thyroid gland growth primarily measured thyroid gland weight. The effect of m icrosom al enzym e inducers on thyroid follicular cell proliferation had not been well investigated. We have shown that small increases in serum TSH can result in large increases in thyroid follicular cell proliferation (18) . Therefore, we hypothesized that those microsom al enzyme inducers that increase serum TSH increase the num ber of proliferating thyroid follicular cells.
We conducted a dose-response study and m easured the num ber of proliferating thyroid follicular cells of rats treated with PB, PCN, 3MC, or PCB (14) . Phenobarbital and PCN treatments, which increased serum TSH ( Figure  2 ), increased thyroid follicular cell proliferation ( Figure  3 , top panel). In contrast to PB and PCN, 3MC and PCB treatm ents, which did not increase serum TSH, did not consistently or appreciably increase thyroid follicular cell proliferation. These results support the hypothesis that thyroid follicular cell proliferation is mediated by TSH.
In agreement with previous studies (18, 41) , we found thyroid follicular cell proliferation to be sensitive to TSH stimulation (14) . We showed that PB and PCN treatments increased serum TSH 65% and 95%, respectively, whereas thyroid follicular cell proliferation, when expressed as a labeling index, was increased 300% and 600% in rats treated with PB or PCN, respectively (14) . The increase in thyroid follicular cell proliferation was even greater, that is, 475% and 975% for PB and PCN, respectively, when expressed as the total num ber of dividing thyroid follicular cells. Despite the dram atic increases in thyroid follicular cell proliferation in rats treated with PB or PCN, the total number of thyroid follicular cells (ie, hyperplasia) was not signi cantly increased (Figure 3 ). This nding suggests that increases in the total cell number are lim ited, perhaps by an increase in thyroid follicular cell apoptosis.
As far as we know, thyroid follicular cell proliferation is the most sensitive indicator of TSH stimulation, as com pared to an increase in thyroid weight, cell hypertrophy, or reduction in colloid space (14) . However, this sensitivity of thyroid follicular cell proliferation is relatively short-lived. Figure 4 shows that the increase in thyroid follicular cell proliferation peaks after 7 days of treatm ent with chemicals that disrupt thyroid hormone homeostasis (17) . The decline in thyroid follicular cell proliferation after 7 days of treatment is thought to be due to desensitization of thyroid follicular cells to the growth-stim ulating action of TSH (32, 40, 41) . Therefore, the desensitization of thyroid follicular cell proliferation to TSH stimulation is a protective mechanism that lim its the growth potential of the thyroid gland. Although this desensitization m echanism is not well understood, it has important implications in thyroid tumorigenesis (32) .
Effects of Microsomal Enzyme Inducers on Outer-Ring Deiodinase Activity
Although microsomal enzym e inducers reduce serum free T 4 , the effect of m icrosom al enzyme inducers on serum -free T 3 is m inimal, as shown in Figure 2 (14) . This nding is consistent with previous studies (2, 8, 23, 25, 26) . It is possible that the increased serum TSH concentration observed in rats treated with PB or PCN plays a role in maintaining serum -free T 3 concentration because TSH stim ulates the thyroid gland to synthesize more T 3 (39) . However, the mechanism by which serum -free T 3 concentration is maintained in 3M C-and PCB-treated rats is unclear because serum TSH is not increased in these rats, as shown in Figure 2 (14) . We proposed that conversion of T 4 to T 3 catalyzed by outer-ring deiodinases (ORD) may explain why serum -free T 3 concentration is maintained in 3MC -and PCB -treated rats (16) .
Outer-ring deiodination is an important pathway for the synthesis of T 3 . For instance, it has been shown that approxim ately 75% of the T 3 found in serum is derived from the conversion of T 4 to T 3 catalyzed by ORD. Most of the T 3 in serum that is synthesized by ORD comes from the thyroid (approximately 55%), whereas liver and kidney ORD provide about 20% (5) . Therefore, increased conversion of T 4 to T 3 , catalyzed by ORD, could provide a mechanism for maintaining serum T 3 concentration.
We found that ORD activity does not appear to play a role in maintaining serum T 3 concentration in rats treated with PB, PCN, 3MC, or PCB. We have shown that thyroid type I ORD activity was not signi cantly increased in PB -, 3MC -, and PCB -treated rats, as shown in Figure  5 (16) . Thyroid type I ORD activity was only slightly increased in PCN-treated rats. Kidney type I ORD activity was unaffected in PB-, PCN -, or 3MC-treated rats and was reduced (65% ) in rats treated with PCB ( Figure 5 ). Liver type I ORD activity was reduced in rats treated with PB, PCN, 3M C, or PCB ( Figure 5 ). Although PB, PCN, and PCB treatm ents increased liver weight (data not shown), it was insuf cient to counteract the reduction in liver type I ORD activity because liver type I ORD activity remained reduced when expressed as picomole I per whole organ per minute (data not shown). Brown adipose tissue type II ORD activity was unchanged in rats treated with either of the 4 microsom al enzyme inducers ( Figure 6 ). Pituitary type II activity was increased in PCN and PCB treated rats and unaffected in PB-and 3MC-treated rats ( Figure 6 ). Although brain type II activity was increased in rats treated with PCN, 3M C, or PCB, it was unaffected in rats treated with PB ( Figure  6 ).
Overall, ORD activity was reduced at the whole-body level, which is in contrast to our hypothesis. Almost all the deiodinase activity in the rat is type I, because type II ORD activity is less than one-thousandth of type I ORD activity. This nding is consistent with other studies showing that type I ORD activity is important in supplying serum with T 3 , whereas type II ORD activity is important in maintaining local tissue levels of T 3 (34) . Therefore, it is unlikely that ORD activity plays a signi cant role in maintaining serum T 3 concentration in rats treated with PB, PCN, 3M C, or PCB.
Although increased ORD activity does not appear to explain why serum T 3 concentration is maintained in rats treated with PB, PCN, 3MC, or PCB, other mechanisms could play a role in maintaining serum T 3 concentration in these rats. For instance, thyroid horm ones (T 4 and T 3 ) are known to be enterohepatically circulated (7, 29, 36) . Therefore, increased enterohepatic circulation could play a role in m aintaining serum T 3 . Another mechanism that could play a role in m aintaining serum T 3 is de novo synthesis catalyzed by thyroid peroxidase. This is plausible because an imbalance in thyroid horm one hom eostasis increases the amount of T 3 that is synthesized, in relation to T 4 (9, 21) . Also, it is known that TSH stimulates all steps of thyroid horm one synthesis within the thyroid gland, including de novo synthesis (31) . A previous study has shown that uptake of 131 I by the thyroid, the rst step in de novo synthesis of thyroid horm ones, is increased in rats treated with PB or PCN (23) . Lastly, although som e microsom al enzyme inducers increase the glucuronidation of T 4 , it is possible that these m icrosomal enzym e inducers do not increase T 3 glucuronidation because T 4 and T 3 are glucuronidated by different UDPglucuronosyltransferases (4).
Effects of Microsomal Enzyme Inducers on Thyroid Hormone UDP-Glucuronosyltransferase Activity in Rats
Increased T 4 UDP-glucuronosyltransferase (UGT) activity is thought to be responsible for the reduction in serum T 4 concentration obser ved in rats treated with microsomal enzyme inducers (1, 2, 8, 15, 23, 24, 30) . We have shown that serum -free T 4 is reduced 45%, 50%, 53%, and 95% in rats treated with PB, PCN, 3MC, or PCB, respectively, as shown in Figure 2 (14) . In addition to the reduction in serum T 4 , these microsom al enzyme inducers increase T 4 UDP-GT activity (Figure 7) , which supports the hypothesis that induction of T 4 glucuronidation m ediates reductions in serum T 4 concentration in rats treated with m icrosomal enzym e inducers (15) . In contrast to T 4 UGT activity, only PB and PCN increase T 3 UDP-GT activity (90% and 200%, respectively) when the activity is expressed per whole organ per minute (Figure 8 ). 3MC and PCB treatments did not have an appreciable effect on T 3 UDP -GT activity (Figure 8) .
In contrast to serum -free T 4 , we have reported in several studies that serum -free T 3 concentration is unaffected in rats treated with PB, PCN, 3M C, or PCB, as shown in Figure 2 (2, 14, 23) . It is unclear why serum T 3 concentration is not reduced, but it suggests that the body maintains serum T 3 concentrations in microsomal enzyme inducer-treated rats. We showed that ORD activity, which catalyzes the conversion of T 4 to T 3 , does not explain why serum T 3 is maintained in these m icrosomal enzym e inducer-treated rats (16) . Other m echanism(s) that may be activated to maintain serum T 3 concentration in microsom al enzyme inducer-treated rats were described previously. EFFECTS ON T 4 , T 3 , AND THE THYROID It has been proposed that the reason PB increases serum TSH is because PB increases the glucuronidation of T 4 , which reduces serum T 4 concentration (24) . Consistent with this hypothesis, we have shown (Figure 2 ) that PB and PCN treatments increase serum TSH (14) . In contrast to this hypothesis, 3M C and PCB treatments do not appreciably affect serum TSH concentration (Figure 2 ). Our previous studies also showed that PB and PCN treatments increase serum TSH concentration, whereas 3MC and PCB do not (2, 23) . These ndings do not support the hypothesis that increased serum TSH in rats treated with microsom al enzyme inducers is a result of increased T 4 glucuronidation and reduced serum T 4 concentration because 3M C and PCB treatments increase T 4 UDP-GT activity (Figure 7) and reduce serum T 4 (Figure 2 ) but do not increase serum TSH (Figure 2) .
We tested the hypothesis that the reason PB and PCN increase serum TSH is because these microsomal enzym e inducers increase the glucuronidation of T 3 (15) . Similarly, the reason 3MC and PCB do not increase serum TSH is because these m icrosomal enzyme inducers do not increase the glucuronidation of T 3 . Results from this study supported this hypothesis because T 3 UGT activity was increased in rats treated with PB or PCN, whereas it was not appreciably affected in rats treated with 3M C or PCB, as shown in Figure 8 (15) . This nding suggested that glucuronidation of T 3 , rather than T 4 , may mediate increases in serum TSH of microsom al enzyme inducertreated rats. The nding that some microsom al enzym e inducers induce T 4 UGT activity but not T 3 UGT activity (ie, 3M C and PCB treatments) suggests that T 4 and T 3 are glucuronidated by different UGT isozymes. This is indeed the case; T 4 is glucuronidated by phenol and bilirubin UGTs (4, 35) , whereas T 3 is glucuronidated by an androsterone UGT (4, 33, 35) . Figure 9 sum marizes our recent work investigating the effects of microsomal enzyme inducers on thyroid follic-ular cell proliferation and thyroid hormone metabolism. We have shown that thyroid follicular cell proliferation is increased in m icrosomal enzyme inducer-treated rats (14, 17) . Furtherm ore, the thyroid follicular cell proliferative response to microsom al enzyme inducer treatm ent is similar to that of antithyroid drugs, which are commonly used to study thyroid gland growth (17) . The increase in the num ber of proliferating thyroid follicular cells of rats treated with microsomal enzym e inducers is a transient response, peaking after 7 days of treatm ent (17) . The decrease after 7 days of treatment is thought to be due to a desensitization mechanism . It has been proposed that breakdown of the desensitization mechanism, which regulates the sensitivity of thyroid follicular cells to the growth-stim ulating action of TSH, is an important step in the development of thyroid tumors (32) . Our most signi cant observation is the nding that only those m icrosom al enzym e inducers that increase serum TSH increase thyroid follicular cell proliferation (ie, PB and PCN) (14) . This nding suggests that thyroid follicular cell proliferation m ay be a useful biomarker for evaluating whether a microsomal enzyme inducer acts as a thyroid horm one disrupter.
CONCLUSION
Not all microsomal enzyme inducers that increase T 4 UGT activity and reduce serum T 4 concentration produce an increase in serum TSH (14, 15, 23) . For instance, 3MC and PCB induce T 4 UGT activity and reduce serum T 4 concentrations but fail to produce a substantial increase in serum TSH. This nding suggests that perhaps T 4 glucuronidation does not m ediate increases in serum TSH. Results from our work suggest that glucuronidation of T 3 , rather than T 4 , mediates increases in serum TSH of rats treated with microsomal enzyme inducers. Only those microsom al enzyme inducers that increase serum TSH (PB and PCN) increase T 3 UDP-GT activity, whereas those m icrosomal enzyme inducers that do not increase serum TSH (3MC and PCB) do not increase T 3 UDP-GT activity (15) . This nding is signi cant because, if it is true, it suggests that assessment of whether microsomal enzyme inducers will increase serum TSH in rats should be based on the glucuronidation of T 3 rather than on the glucuronidation of T 4 .
